Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance

(E-pub Ahead of Print)

Author(s): Tomohito Wakabayashi, Takahiro Nakatsuji, Hiroko Kambara, Iku Niinomi, Saki Oyama, Ayaka Inada, Sayaka Ueno, Mayako Uchida, Kazunori Iwanaga, Tatsuya Iida, Keiko Hosohata*

Journal Name: Current Reviews in Clinical and Experimental Pharmacology
(Formerly Current Clinical Pharmacology)

Become EABM
Become Reviewer
Call for Editor


Background: Several studies reported that abnormal behavior was noted in pediatric patients receiving several drugs, including neuraminidase inhibitors (NIs). However, the information on drugs associated with abnormal behavior in a real-world setting remains limited. The purpose of this study was to clarify the drugs associated with abnormal behavior using a spontaneous reporting system database.

Methods: We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency were analyzed, and the reporting odds ratio at 95% confidence interval were calculated.

Results: A total of 1,144 reports of abnormal behavior were identified. The signals were detected through the association of 4 neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) with the abnormal behaviour. These signals were stronger for oseltamivir than other neuraminidase inhibitors. The signals were also detected for acetaminophen and montelukast.

Conclusion: Our results should be able to raise physicians’ awareness of drugs associated with abnormal behavior, but further investigation of these medications is warranted.

Keywords: Adverse events, spontaneous reporting system, reporting odds ratio, Japanese Adverse Drug Event Report (JADER) database.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1574884716666210215104540
Price: $95

Article Metrics

PDF: 1